Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.

Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States.

Patients with clinically suspect arthralgia (CSA), a common prequel to rheumatoid arthritis (RA), showed different patterns of symptoms and progression depending on whether they tested positive for anti-citrullinated protein antibodies (ACPA), researchers found.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). Guselkumab is an IL-23 inhibitor indicated for use in psoriasis, psoriatic arthritis, ulcerative colitis and Crohn's disease.